CIK 0001042418 · Non-accelerated filer<br>Smaller reporting company
Inhibitor Therapeutics, Inc.
Sign in to watch- Ticker
- INTI
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 541641133
- Phone
- (813) 766-2462
- Business address
- 4830 W. KENNEDY BLVD., SUITE 600, TAMPA, FL, 33609
- Former names
- HedgePath Pharmaceuticals, Inc., COMMONWEALTH BIOTECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-03 | Martin Robert Daniel Director | Grant or award · Common Stock Option | +657,895 | 657,895 | ||
| 2019-02-03 | Watson W. Mark Director | Grant or award · Common Stock Option | +657,895 | 657,895 | ||
| 2019-02-03 | MAGRAB E. BRENDAN Director | Grant or award · Common Stock Options | +986,842 | 986,842 | ||
| 2019-01-15 | Mayne Pharma Ventures Pty Ltd 10% owner | Other acquisition | +362,121 | 198,653,051 | ||
| 2018-12-20 | Martin Robert Daniel Director | Grant or award | +60,000 | $0.08 | $5K | 116,000 |
| 2018-12-20 | MAGRAB E. BRENDAN Director | Grant or award | +65,000 | $0.08 | $5K | 65,000 |
| 2018-08-30 | Hasara Garrison J. CFO and Treasurer | Sale | −100,000 | $0.27 | $27K | 3,959,044 |
| 2018-07-15 | Mayne Pharma Ventures Pty Ltd 10% owner | Other acquisition | +184,798 | 198,290,930 | ||
| 2018-07-05 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series B Convertible Preferred Stock | +2,318,841 | 5,797,102 | ||
| 2018-07-05 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series A Warrants to Purchase Common Stock | +1,739,131 | 1,739,131 | ||
| 2018-07-05 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series B Warrants to Purchase Common Stock | +1,739,131 | 1,739,131 | ||
| 2018-03-13 | Martin Robert Daniel Director | Grant or award · Common Stock Option | +253,000 | 253,000 | ||
| 2018-03-13 | Martin Robert Daniel Director | Grant or award · Common Stock Option | +56,000 | 56,000 | ||
| 2018-03-13 | MAGRAB E. BRENDAN Chairman of the Board | Grant or award · Common Stock Options | +345,000 | 345,000 | ||
| 2018-03-13 | Ono Richard Dana Director | Grant or award · Common Stock Option | +253,000 | 253,000 | ||
| 2018-03-13 | Ono Richard Dana Director | Grant or award · Common Stock Option | +56,000 | 56,000 | ||
| 2018-03-13 | Watson W. Mark Director | Grant or award · Common Stock Option | +253,000 | 253,000 | ||
| 2018-03-13 | Watson W. Mark Director | Grant or award · Common Stock Option | +76,000 | 76,000 | ||
| 2018-03-13 | Hasara Garrison J. CFO and Treasurer | Grant or award · Common Stock Option | +260,000 | 260,000 | ||
| 2018-03-13 | VIRCA NICHOLAS J President and CEO | Grant or award · Common Stock Option | +310,000 | 310,000 |
Page 3 of 9 · 165 trades